A radioprotective effect of imatinib (Gleevec®) in human squamous carcinoma cells

Strahlentherapie und Onkologie

Volumn 183, Issue 8, 2007, Pages 432-439

  Bartkowiak, Detlef ^a   Hipp, Peter R ^a   Mendonca, Marc S ^b   Röttinger, Erwin M ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gleevec ; Imatinib; Protection; Radiation

Indexed keywords

DNA; IMATINIB; RAD51 PROTEIN;

ARTICLE; CELL CYCLE; CELL SURVIVAL; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG EFFECT; DRUG STABILITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; PHENOTYPE; RADIATION INJURY; RADIATION PROTECTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PIPERAZINES; PYRIMIDINES; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS;

EID: 34547761276     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1680-7     Document Type: Article

References (39)

1. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
2. Baierlein SA, Distel L, Sieber R, et al. Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells. Strahlenther Onkol 2006;182:467-72.
3. Bartkowiak D, Högner S, Baust H, et al. Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate. Cytometry 1999;37:191-6.
4. Bartkowiak D, Högner S, Nothdurft W, et al. Cell cycle and growth response of CHO cells to X-irradiation: threshold-free repair at low doses. Int J Radiat Oncol Biol Phys 2001;50:221-7.
5. Bartkowiak D, Nothdurft W, Röttinger EM. Differential proliferation dependence of alpha and beta damage in X-irradiated Chinese hamster cells. Strahlenther Onkol 1999;175:239-44.
6. Belyakov OV, Prise KM, Trott KR, et al. Delayed lethality, apoptosis and micronucleus formation in human fibroblasts irradiated with X-rays or alpha-particles. Int J Radiat Biol 1999;75:985-93.
7. Brunner TB, Hahn SM, McKenna WG, et al. Radiation sensitization by inhibition of activated Ras. Strahlenther Onkol 2004;180:731-40.
8. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
9. Burdak-Rothkamm S, Rube CE, Nguyen TP, et al. Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa®). Strahlenther Onkol 2005;181:197-204.
10. Carbonari M, Cibati M, Cherchi M, et al. Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocytometric method. Blood 1994;83:1268-77.
11. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992;80:2735-9.
12. Corbin S, La Rosée P, Stoffregen EP, et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611-4.
13. D'Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12:44-56.
14. De Mestier P, des Guetz G. Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J Surg 2005; 29:357-61.
15. Druker J, Sawyers CL, Kantarjian H, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
16. Fehm T, Maul H, Gebauer, S et al. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor. Strahlenther Onkol 2005;181:580-6.
17. Fertil B, Dertinger H, Courdi A, et al. Mean inactivation dose: a useful concept for intercomparison of human cell survival. Radiat Res 1984;99:73-84.
18. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
19. Holdhoff M, Kreuzer KA, Appelt C, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005;34:181-5.
20. Karlsson KH, Stenerlöw B. Focus formation of DNA repair proteins in normal and repair-deficient cells irradiated with high-LET ions. Radiat Res 2004;161:517-27.
21. Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer 2005;103:2128-31.
22. Larminat F, Germanier M, Papouli E, et al. Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant. Biol Cell 2004;96:545-52.
23. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-73.
24. Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004;10:681-90.
25. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2003:132-52.
26. Merchant MS, Woo CW, Mackall CL, et al. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-9.
27. Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004;101:3130-5.
28. Oertel S, Krempien R, Lindel K, et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec®). Strahlenther Onkol 2006;182:400-7.
29. Ohashi A, Kinoshita K, Isozaki K, et al. Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. Int J Cancer 2004;111:317-21.
30. Podtcheko A, Ohtsuru A, Namba H, et al. Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells. Radiat Res 2006;165:35-42.
31. Raderschall E, Bazarov A, Cao J, et al. Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis. J Cell Sci 2002;115:153-64.
32. Rapp A, Greulich KO. After double-strand break induction by UV-A, homologous recombination and nonhomologous end joining cooperate at the same DSB if both systems are available. J Cell Sci 2004;117:4935-45.
33. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002;99:10700-5.
34. Russell JS, Brady K, Burgan WE, et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003;63:7377-83.
35. Schmandt RE, Broaddus R, Lu KH, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003;98:758-64.
36. Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001;8:795-806.
37. Sørensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005;7:195-201.
38. Yuan ZM, Huang Y, Ishiko Tm et al. Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 1998;273:3799-802.
39. Zhang P, Gao WY, Turner S, et al. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003;2:1. (DOI: 10.1186/1476-4598-2-1).